Are Private Equity Firms the New Health-Care Fraud Target?

Private equity firms were placed on notice recently they may fall into an expanding False Claims Act liability net after the DOJ revealed it will proceed against one such firm for alleged fraud by a compounding pharmacy in which it held a majority stake.  Justin C. Linder discussed the implications of the DOJ’s decision to intervene in U.S. ex rel. Medrano v. Diabetic Care Rx, LLC in the June 1 issue of Bloomberg Law News.

Read the complete article: Are Private Equity Firms the New Health-Care Fraud Target?